Olaparib, a new hope for ovarian cancer

被引：0
|
作者：
Samoon, Zarka [1 ]
Jabbar, Adnan Abdul [1 ]
机构：
[1] Aga Khan Univ Hosp, Dept Oncol, Karachi, Pakistan
来源：
INDIAN JOURNAL OF CANCER | 2020年 / 57卷 / 03期
关键词：
MAINTENANCE THERAPY; PHASE-2; PARP;
D O I：
10.4103/ijc.IJC_1_19
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：346 / 347
页数：2
相关论文
共 50 条
  • [41] New Therapies for Ovarian Cancer
    O'Malley, David M.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (05): : 619 - 621
  • [42] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
    Cho, Angela
    Park, Jeong-Yeol
    Lee, Shin-Wha
    Kim, Dae-Yeon
    Suh, Dae-Shik
    Kim, Jong-Hyeok
    Kim, Yong-Man
    Kim, Young-Tak
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2021, 304 (04) : 1055 - 1063
  • [43] Pharmacological issues concerning olaparib capsule and tablet formulations in treating ovarian cancer: Are they really the same drug?
    Perego, Gianluca
    Nozza, Renata
    Oggionni, Emanuela
    Cabiddu, Mary
    Scolari, Cinzia
    Omati, Elena
    Castelli, Emanuela A.
    Petrelli, Fausto
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020, 26 (04) : 967 - 971
  • [44] Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
    Gunderson, Camille C.
    Moore, Kathleen N.
    FUTURE ONCOLOGY, 2015, 11 (05) : 747 - 757
  • [45] Experience with olaparib in the treatment of recurrent ovarian epithelial cancer with mutations in the BRCA 1 and BRCA 2 genes
    Erik, Skof
    ONKOLOGIJA, 2021, 25 (01) : 12 - 16
  • [46] Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer
    Wilson, Andrew J.
    Gupta, Vijayalaxmi G.
    Liu, Qi
    Yull, Fiona
    Crispens, Marta A.
    Khabele, Dineo
    NEOPLASIA, 2022, 24 (02): : 63 - 75
  • [47] Safety of bevacizumab and olaparib as frontline maintenance therapy in advanced ovarian cancer: expert review for clinical practice
    Romero, Ignacio
    Guerra, Eva
    Madariaga, Ainhoa
    Manso, Luis
    FRONTIERS IN ONCOLOGY, 2024, 13
  • [48] Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer
    Angela Cho
    Jeong-Yeol Park
    Shin-Wha Lee
    Dae-Yeon Kim
    Dae-Shik Suh
    Jong-Hyeok Kim
    Yong-Man Kim
    Young-Tak Kim
    Archives of Gynecology and Obstetrics, 2021, 304 : 1055 - 1063
  • [49] Olaparib for advanced breast cancer
    Griguolo, Gaia
    Dieci, Maria Vittoria
    Miglietta, Federica
    Guarneri, Valentina
    Conte, PierFranco
    FUTURE ONCOLOGY, 2020, 16 (12) : 717 - 732
  • [50] Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
    Oza, Amit M.
    Cibula, David
    Oaknin Benzaquen, Ana
    Poole, Christopher
    Mathijssen, Ron H. J.
    Sonke, Gabe S.
    Colombo, Nicoletta
    Spacek, Jiri
    Vuylsteke, Peter
    Hirte, Holger
    Mahner, Sven
    Plante, Marie
    Schmalfeldt, Barbara
    Mackay, Helen
    Rowbottom, Jacqui
    Lowe, Elizabeth S.
    Dougherty, Brian
    Barrett, J. Carl
    Friedlander, Michael
    LANCET ONCOLOGY, 2015, 16 (01) : 87 - 97
12345